Format

Send to

Choose Destination
J Mol Endocrinol. 2017 Oct;59(3):R109-R120. doi: 10.1530/JME-17-0117. Epub 2017 Jul 24.

Therapeutic potential of mesenchymal stem cells for diabetes.

Author information

1
Department of PediatricsUniversity of Texas Health Science Center-San Antonio, San Antonio, Texas, USA moreiraa@uthscsa.edu.
2
Department of PediatricsUniversity of Texas Health Science Center-San Antonio, San Antonio, Texas, USA.
3
Department of PhysiologyTexas Research Park Campus, Barshop Institute for Longevity and Aging Studies, San Antonio, Texas, USA.

Abstract

Mesenchymal stem cells (MSCs) are self-renewing multipotent cells that have the capacity to secrete multiple biologic factors that can restore and repair injured tissues. Preclinical and clinical evidence have substantiated the therapeutic benefit of MSCs in various medical conditions. Currently, MSCs are the most commonly used cell-based therapy in clinical trials because of their regenerative effects, ease of isolation and low immunogenicity. Experimental and clinical studies have provided promising results using MSCs to treat diabetes. This review will summarize the role of MSCs on tissue repair, provide emerging strategies to improve MSC function and describe how these processes translate to clinical treatments for diabetes.

KEYWORDS:

diabetes; endocrine; mesenchymal stem cell; tissue regeneration

PMID:
28739632
PMCID:
PMC5570611
DOI:
10.1530/JME-17-0117
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Sheridan PubFactory Icon for PubMed Central
Loading ...
Support Center